Waldenstrom's Macroglobulinemia
The latest news, research, and perspectives in Waldenstrom's macroglobulinemia (WM).
Advertisement
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
The safety results from this phase 2 trial were also consistent with those observed in other studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The evolving role of HSCT aAHSCT, and allo-HSCT requires further clarification amid new treatment advances in WM.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Zanubrutinib was linked with increased treatment duration and reduced risk of dose reduction or discontinuation due to AEs.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
More than one-quarter of the patients required a dose reduction due to adverse events.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.